Ланзап®

General characteristics. Structure:

Each capsule contains 30 mg of a lansoprazol.
Excipients: Mannitolum, magnesium carbonate, lactose, calcium carboxymethylcellulose, sucrose, povidone, sodium methylparaben, propylparaben of sodium, gidroksipropilmetiltsellyuloz phthalate, cetyl alcohol, titanium dioxide.

Description
solid gelatin capsules, white or almost white with cream shade, 1 size. Capsules have marking of "lanzap" on the case and a cover. Capsule contents - granules of white or almost white color.

Pharmacological properties:

Pharmacodynamics. Antiulcerous means. Specific inhibitor of the protonew pump (N + to + ATP-ases); it is metabolized in covering cells of a stomach to active sulphonamide derivatives which inactivate sulphhydryl groups of N + to + ATP-ases. Blocks a final stage of synthesis of hydrochloric acid, reducing basal and stimulated secretion, irrespective of the irritant nature. Braking of products of hydrochloric acid at a dose of 30 mg - 80-97%. Does not influence motility of a GIT. The inhibiting effect increases in the first four days of reception. After the reception termination acidity within 39 hours remains lower than 50% of basal level, "ricochet" increase in secretion is not noted. Secretory activity is recovered in 3-4 days after the end of administration of drug. At patients with a syndrome of a zollingera-ellison works more for a long time.

Pharmacokinetics. Absorption - high (meal reduces absorption and bioavailability, but the braking influence on gastric secretion remains identical, irrespective of meal). Time of approach of the maximum concentration (cmax) after oral administration of 30 mg - 1,5-2,2 h, сmах-0,75 - 1,15 mg/l. Communication with proteins of plasma - 97,7-99,4%. It is actively metabolized at primary passing through a liver. An elimination half-life of 1,3-1,7 h excretion kidneys (in the form of metabolites) - 14-23% and through intestines. At a liver failure and at elderly patients removal is slowed down.

Indications to use:

- Peptic ulcer of a stomach and duodenum.
- reflux esophagitis, erosive and ulcer esophagitis.
- the erosive cankers of a stomach and duodenum connected with reception нпвп, stressful ulcers.
- the erosive cankers of a stomach and duodenum associated with helicobacter pylori (as a part of complex therapy).
- a syndrome of a zollinger - an ellison.

Route of administration and doses:

Inside. Capsules should be swallowed entirely, without chewing.
Peptic ulcer of a duodenum in an aggravation phase - on 30 mg a day within 2-4 weeks (in resistant cases to 60 mg a day).
Peptic ulcer an eyueludka in a phase of an aggravation and an erosive and ulcer esophagitis - on 30 - 60 mg a day within 4 - 8 weeks.
The GIT erosive cankers caused by reception нпвп - on 30 mg a day within 4-8 weeks.
Eradikation helicobacter pylori - on 30 mg 2 times a day within 10-14 days in combination with antibacterial agents.
Antirecurrent treatment of a peptic ulcer of a stomach and 12-perstny gut - on 30 mg a day.
Antirecurrent treatment a reflux esophagitis - 30 mg a day for a long time (up to 6 months).
The syndrome of a zollingera-ellison - a dose is selected individually before achievement of level of basal secretion less than 10 mmol/h.

Features of use:

Before an initiation of treatment it is necessary to exclude existence of malignant process in upper parts of a GIT since. Administration of drug can "mask" symptomatology and complicate diagnosis.

Side effects:

From the alimentary system: increase or loss of appetite, nausea, abdominal pain; seldom - diarrhea or a lock; in some cases - ulcer colitis, digestive tract candidiasis, increase in activity of "hepatic" enzymes, increase in level of bilirubin in blood.
From a nervous system: a headache, it is rare - an indisposition, dizziness, drowsiness, a depression, alarm.
From respiratory system: seldom - cough, pharyngitis, rhinitis, an upper respiratory tract infection, a grippopodobny syndrome.
From bodies of a hemopoiesis: seldom - thrombocytopenia (with hemorrhagic manifestations); in some cases - anemia.

Allergic reactions: skin rash; in some cases - a photosensitization, a multiformny erythema.
Others: seldom - a mialgiya, an alopecia.

Interaction with other medicines:

Slows down elimination of the medicines which are metabolized in a liver by a microsomal oxidation (including. Diazepam, Phenytoinum, indirect anticoagulants). Reduces clearance of theophylline by 10%. Changes rn-dependent absorption of the medicines relating to groups of weak acids (delay) and the bases (acceleration). Sukralfat reduces bioavailability of a lansoprazol by 30% (it is necessary to observe an interval between reception of these drugs of 30-40 minutes) antacids slow down and reduce absorption of a lansoprazol (them it is necessary to appoint in 1 hour or in 1-2 hours after reception of a lansoprazol).

Contraindications:

Hypersensitivity to drug components, malignant new growths of a GIT, pregnancy (i a trimester), the lactation period, age up to 18 years.
With care - a liver and/or renal failure, pregnancy (ii-iii a trimester), advanced age.

Storage conditions:

Period of validity 2 years. Not to apply after the period of validity specified on packaging. In dry, protected from light, the place, unavailable to children, at a temperature up to 25 °C.

Issue conditions:

According to the recipe

Packaging:

Capsules on 30 mg. 10 capsules in the blister, 2 blisters are packed together with the application instruction into a cardboard box.